Merit reported nine-month sales of $1,217.0 million, up 8.5%, and net income of $122.1 million versus $90.5 million; third-quarter sales rose 8.4% to $416.2 million, and cash, cash equivalents and restricted cash totaled $505.8 million.
MMSI · Merit Medical Systems Inc · Documents
$86.29
-0.35 (-0.40%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$5.19B
Shares
59.92M
Volume · Nov 16
61K
Avg daily vol (3M)
669.51K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Oct 29
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3
Revenue $416.24M
▲ 8.4%
Net income $42.31M
▲ 52.4%
Diluted EPS $0.70
▲ 52.2%
Oct 29
Current report
8-K
9% organic growth, raised guidance, Solo Pace acquisition
Merit Medical Systems, Inc. reported third-quarter revenue of $416.2 million, up 8.4%, with 9% organic constant-currency growth, and raised 2026 guidance. It also acquired Solo Pace on October 13, 2026 for approximately $45 million in cash.
Sep 10
Aug 20
Current report
8-K
Events of Aug 14
Director or officer change, or executive pay, Regulation FD disclosure
AI summary on its way
Aug 11
Jul 30
Jul 30
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $418.84M
▲ 9.5%
Net income $38.8M
▲ 19.1%
Diluted EPS $0.65
▲ 20.4%
Jul 30
Jun 8
May 19
Current report
8-K
Events of May 13
Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Shareholder vote results, Regulation FD disclosure
AI summary on its way
May 12
May 12
Apr 30
Apr 30
Apr 30
Quarterly report
10-Q
FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1
AI summary on its way
Revenue $381.88M
▲ 7.5%
Net income $41M
▲ 36.0%
Diluted EPS $0.68
▲ 38.8%
Apr 13
Apr 1
Mar 31
Mar 31
Mar 31
Feb 24
Feb 24
Feb 24
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Revenue $1.52B
▲ 11.8%
Net income $128.49M
▲ 6.8%
Diluted EPS $2.13
▲ 4.9%
Jan 8
Current report
8-K
Events of Jan 4
Financial results, Director or officer change, or executive pay, Regulation FD disclosure
AI summary on its way
2025
Nov 13
Current report
8-K
Regulation FD disclosure
Nov 3
Current report
8-K
Regulation FD disclosure
Oct 30
Earnings call
Q3 2025 earnings call
Oct 30
Current report
8-K
Financial results, Regulation FD disclosure
Oct 30
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $384.16M
▲ 13.0%
Net income $27.76M
▼ 2.4%
Diluted EPS $0.46
▼ 4.2%
Oct 17
Current report
8-K
Events of Oct 15
Regulation FD disclosure
Oct 10
Current report
8-K
Events of Oct 3
Director or officer change, or executive pay
Jul 30
Earnings call
Q2 2025 earnings call
Jul 30
Current report
8-K
Financial results, Regulation FD disclosure
Jul 30
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $382.46M
▲ 13.2%
Net income $32.58M
▼ 8.8%
Diluted EPS $0.54
▼ 11.5%
Jul 11
Current report
8-K
Events of Jul 7
Financial results, Director or officer change, or executive pay
May 20
Current report
8-K
Events of May 16
Entered into a material agreement, Financial results, Regulation FD disclosure
May 19
Current report
8-K
Events of May 14
Shareholder vote results
Apr 24
Earnings call
Q1 2025 earnings call
Apr 24
Current report
8-K
Financial results, Regulation FD disclosure
Apr 24
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $355.35M
▲ 9.8%
Net income $30.15M
▲ 6.8%
Diluted EPS $0.49
▲ 2.1%
Apr 14
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2024
Apr 1
Proxy statement
DEF 14A
Proxy statement
Apr 1
Annual report to holders
ARS
Annual report to holders
Apr 1
Proxy statement
DEFA14A
Proxy statement
Feb 25
Earnings call
Q4 2024 earnings call
Feb 25
Current report
8-K
Financial results, Regulation FD disclosure
Feb 25
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Revenue $1.36B
▲ 7.9%
Net income $120.36M
▲ 27.5%
Diluted EPS $2.03
▲ 25.3%
Jan 28
Current report
8-K
Regulation FD disclosure
Jan 14
Current report
8-K
Events of Jan 13
Financial results, Regulation FD disclosure
2024
Dec 19
Current report
8-K
Events of Dec 16
Director or officer change, or executive pay, Regulation FD disclosure
Showing 1–50 of 151 documents
Key facts
CIK
856982
CUSIP
589889104
13F (30d)
339 filings
302 filers
Visit website
Investor relations